Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A

被引:35
作者
Johnson, Tara L.
Lai, Maria B.
Lai, James C. K.
Bhushan, Alok
机构
[1] Idaho State Univ, Coll Pharm, Dept Biomed & Pharmaceut Sci, Pocatello, ID 83209 USA
[2] Idaho State Univ, Biomed Res Inst, Pocatello, ID 83209 USA
关键词
oral cancer; isoflavones; cell signalling; cancer prevention; IN-VITRO; CANCER; EXPRESSION; MODEL; HEAD; CHEMOPREVENTION; TARGET; DEATH;
D O I
10.1093/ecam/nen011
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
High morbidity and mortality associated with oral squamous cell carcinoma (OSCC) are largely attributable to late stage diagnosis. Despite significant advances in therapeutic strategies, the five-year survival rate for oral cancer remains at about 50%. A chemopreventive approach may be an effective alternative or adjunct to current therapies. Previous studies have shown antitumor effects of isoflavones in several cancers, including oral cancer. However, their mechanisms of action are still unclear. We hypothesized that isoflavones inhibit multiple signaling pathways implicated in oral carcinogenesis. To address our hypothesis, we investigated the effects of three isoflavone derivatives, genistein, biochanin A and daidzein, on SCC15 and SCC25 squamous cell carcinoma cell lines. In cell proliferation experiments, we found that genistein and biochanin A inhibited SCC15 and SCC25 cell growth with an IC50 of 50 mu M. We also investigated the effect of isoflavones on ERK and Akt pathways. Our results, from western blot analysis, suggest that both genistein and biochanin A induced decreases in phosphorylation of ERK and Akt at treatment concentrations of 20, 50 and 100 mu M. Taken together, our results clearly demonstrate a differential regulation of signaling pathways by various isoflavones in OSCC cell lines. Thus, tumor progression models can be utilized to study the preventive and therapeutic roles of isoflavones in oral cancer cell lines.
引用
收藏
页码:351 / 358
页数:8
相关论文
共 39 条
[1]   Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro:: Possible involvement of inhibition of survival signal transduction pathways [J].
Akimoto, T ;
Nonaka, T ;
Ishikawa, H ;
Sakurai, H ;
Saitoh, J ;
Takahashi, T ;
Mitsuhashi, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (01) :195-201
[2]  
AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
[3]  
Alhasan SA, 2000, INT J ONCOL, V16, P333
[4]   Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 [J].
Amornphimoltham, P ;
Sriuranpong, V ;
Patel, V ;
Benavides, F ;
Conti, CJ ;
Sauk, J ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4029-4037
[5]  
Arvind R, 2005, INT J ONCOL, V27, P1499
[6]   EFFECTS OF PROTEIN-TYROSINE KINASE INHIBITORS WITH DIFFERENT MODES OF ACTION ON TOPOISOMERASE ACTIVITY AND DEATH OF IL-2-DEPENDENT CTLL-2 CELLS [J].
AZUMA, Y ;
ONISHI, Y ;
SATO, Y ;
KIZAKI, H .
JOURNAL OF BIOCHEMISTRY, 1995, 118 (02) :312-318
[7]   Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer [J].
Banerjee, S ;
Zhang, YX ;
Ali, S ;
Bhuiyan, M ;
Wang, ZW ;
Chiao, PJ ;
Philip, PA ;
Abbruzzese, J ;
Sarkar, FH .
CANCER RESEARCH, 2005, 65 (19) :9064-9072
[8]   Health effects of phytoestrogens [J].
Branca, F ;
Lorenzetti, S .
DIET DIVERSIFICATION AND HEALTH PROMOTION, 2005, 57 :100-111
[9]  
Cao F, 2006, BIOMED ENVIRON SCI, V19, P35
[10]   Indigofera suffruticosa:: An alternative anticancer therapy [J].
Cardoso Vieira, Jeymesson Raphael ;
de Souza, Ivone Antonia ;
do Nascimento, Silene Carneiro ;
Leite, Sonia Pereira .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2007, 4 (03) :355-359